Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

EuroPCR 2023 | Provisional Stenting is Still the First Choice

The EBC TWO in Non-LM study randomized 200 patients with bifurcation lesions not affecting the left main coronary artery (LCA) to receive provisional stenting vs. culotte (Norobi stent).

The secondary branch had to have a diameter ≥2.5 mm and a lesion length >5 mm. The crossover of those who received provisional stenting to the two-stent strategy was 16%.

After 12 months of follow-up, major adverse cardiac events (MACE) rates were similar for provisional stenting and culotte (7.7% vs. 10.3%; p = 0.53).

After 5 years of follow-up, there were no differences in all-cause mortality, infarction, or target-vessel failure, nor in interaction when the secondary branch lesion was larger or smaller than 10 mm.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the editorial board of SOLACI.org.

Reference: EBC TWO in Non-LM Lesions, presentado por el Dr. Sandeep Arunothayaraj en el Congreso EuroPCR 2023, realizado en París, Francia.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...